{"id":27561,"date":"2024-04-10T09:26:25","date_gmt":"2024-04-10T03:56:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27561"},"modified":"2024-04-10T09:26:27","modified_gmt":"2024-04-10T03:56:27","slug":"alectinib-promising-efficacy-and-tolerability","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability","title":{"rendered":"Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I\/II open-label, multi-center study"},"content":{"rendered":"\n<p>According to the data presented at the AACR 2024 conference, as of the data cutoff date of <strong>June 12, 2023, <\/strong>a total of 8 patients at a median age of 11 years diagnosed with inflammatory myofibroblastic tumor (n=2), high-grade glioma (n=3), renal cell carcinoma (n=2), and anaplastic large cell lymphoma (n=1, protocol deviation) were enrolled. Among 7 patients evaluable for efficacy, 6 had not received prior systemic therapy. Furthermore, the ALK fusion partners were KIF5C in 2 patients and TPM3, CLTC, PLEKHA7, DCTN1, and HNRNPA3 in 1 patient each. Apart from that, the median treatment duration was 12 months, and no dose-limiting toxicities were reported.<\/p>\n\n\n\n<p>Investigators reported the Best Overall Responses as follows: in 4 patients (57.1%; 1 CR, 3 PR), 2 patients (28.6%) with Stable Disease, and 1 patient had not undergone a tumor assessment at the time of data cut-off. In terms of safety, 7 patients experienced a related Adverse Event (AE) including 2 patients with Grade \u2265 3 related AE. There were no AE-related deaths, and no new safety signals were detected.<\/p>\n\n\n\n<p><strong>Conclusion<\/strong><\/p>\n\n\n\n<p>In pediatric patients with ALK-fusion positive solid or CNS tumors, alectinib exhibits promising efficacy alongside favorable tolerability, offering hope in this challenging population with the majority of patients responding positively, thus presenting a compelling benefit-risk profile.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>According to the data presented at the AACR 2024 conference, as of the data cutoff date of June 12, 2023, a total of 8 patients at a median age of 11 years diagnosed with inflammatory myofibroblastic tumor (n=2), high-grade glioma (n=3), renal cell carcinoma (n=2), and anaplastic large cell lymphoma (n=1, protocol deviation) were enrolled. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":27562,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[3057,22035,20587],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-27561","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aacr","tag-aacr-2024","tag-aacr-conference","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alectinib: Promising Efficacy and Tolerability | AACR 2024<\/title>\n<meta name=\"description\" content=\"In pediatric patients with ALK-fusion positive solid or CNS tumors, alectinib exhibits promising efficacy alongside favorable tolerability\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alectinib: Promising Efficacy and Tolerability | AACR 2024\" \/>\n<meta property=\"og:description\" content=\"In pediatric patients with ALK-fusion positive solid or CNS tumors, alectinib exhibits promising efficacy alongside favorable tolerability\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-10T03:56:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-10T03:56:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092606\/alectinib-promising-efficacy-and-tolerability.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alectinib: Promising Efficacy and Tolerability | AACR 2024","description":"In pediatric patients with ALK-fusion positive solid or CNS tumors, alectinib exhibits promising efficacy alongside favorable tolerability","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability","og_locale":"en_US","og_type":"article","og_title":"Alectinib: Promising Efficacy and Tolerability | AACR 2024","og_description":"In pediatric patients with ALK-fusion positive solid or CNS tumors, alectinib exhibits promising efficacy alongside favorable tolerability","og_url":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-04-10T03:56:25+00:00","article_modified_time":"2024-04-10T03:56:27+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092606\/alectinib-promising-efficacy-and-tolerability.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability","url":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability","name":"Alectinib: Promising Efficacy and Tolerability | AACR 2024","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092606\/alectinib-promising-efficacy-and-tolerability.png","datePublished":"2024-04-10T03:56:25+00:00","dateModified":"2024-04-10T03:56:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"In pediatric patients with ALK-fusion positive solid or CNS tumors, alectinib exhibits promising efficacy alongside favorable tolerability","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/alectinib-promising-efficacy-and-tolerability#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092606\/alectinib-promising-efficacy-and-tolerability.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092606\/alectinib-promising-efficacy-and-tolerability.png","width":466,"height":284,"caption":"alectinib-promising-efficacy-and-tolerability"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092606\/alectinib-promising-efficacy-and-tolerability-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AACR<\/span>","<span class=\"advgb-post-tax-term\">AACR 2024<\/span>","<span class=\"advgb-post-tax-term\">AACR Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 10, 2024","modified":"Updated on Apr 10, 2024"},"absolute_dates_time":{"created":"Posted on Apr 10, 2024 9:26 am","modified":"Updated on Apr 10, 2024 9:26 am"},"featured_img_caption":"alectinib-promising-efficacy-and-tolerability","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27561"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27561\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27562"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27561"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27561"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}